X0407 4 2023-04-11 0 0001607678 Viking Therapeutics, Inc. VKTX 0001264949 ZANTE GREG C/O VIKING THERAPEUTICS, INC. 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 0 1 0 0 Chief Financial Officer 0 Common Stock, par value $0.00001 per share 2023-04-11 4 M 0 3242 7.77 A 152521 D Common Stock, par value $0.00001 per share 2023-04-11 4 M 0 8500 4.68 A 161021 D Common Stock, par value $0.00001 per share 2023-04-11 4 M 0 30000 4.88 A 191021 D Common Stock, par value $0.00001 per share 2023-04-11 4 M 0 14553 5.80 A 205574 D Common Stock, par value $0.00001 per share 2023-04-11 4 S 0 56295 18.0037 D 149279 D Common Stock, par value $0.00001 per share 2023-04-12 4 M 0 37447 5.80 A 186726 D Common Stock, par value $0.00001 per share 2023-04-12 4 M 0 4097 7.77 A 190823 D Common Stock, par value $0.00001 per share 2023-04-12 4 S 0 41544 18.00 D 149279 D Stock Option (right to buy) 7.77 2023-04-11 4 M 0 3242 0.00 D 2021-01-03 2030-01-03 Common Stock 3242 16847 D Stock Option (right to buy 4.68 2023-04-11 4 M 0 8500 0.00 D 2021-03-31 2030-03-31 Common Stock 8500 8500 D Stock Option (right to buy 4.88 2023-04-11 4 M 0 30000 0.00 D 2023-01-03 2032-01-03 Common Stock 30000 90000 D Stock Option (right to buy 5.80 2023-04-11 4 M 0 14553 0.00 D 2022-01-04 2031-01-04 Common Stock 14553 63447 D Stock Option (right to buy 5.80 2023-04-12 4 M 0 37447 0.00 D 2022-01-04 2031-01-04 Common Stock 37447 26000 D Stock Option (right to buy) 7.77 2023-04-12 4 M 0 4097 0.00 D 2021-01-03 2030-01-03 Common Stock 4097 12750 D The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. 25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date. The Form 4 filed by the Reporting Person on April 3, 2023 reporting, among other things, the exercise of 30,911 shares subject to this option on April 3, 2023 inadvertently indicated that there were 0 shares remaining subject to this option after such exercise. That Form 4 should have reflected that there were 20,089 shares remaining subject to this option after such exercise and the balance has been adjusted accordingly in this Form 4. One-third of the shares subject to the option vested or will vest on each one year anniversary of the grant date. /s/ Michael Morneau as Attorney-in-Fact 2023-04-13